Recent Stock Option Grants by Protara Therapeutics
Protara Therapeutics, Inc. (Nasdaq: TARA), a leading clinical-stage biotechnology firm, is at the forefront of developing innovative therapies targeted at cancer and rare diseases. Recently, the company reported the granting of inducement non-qualified stock options and restricted stock units (RSUs) to six newly hired employees. This move reflects Protara's commitment to attracting top talent as they progress in their mission.
Details of the Inducement Grants
The independent members of Protara's Board of Directors have approved these grants under the company's 2020 Inducement Plan. Notably, Shane Williams, the newly appointed Vice President and Chief People Officer, was awarded 41,000 stock option awards, along with 20,500 RSUs. These grants are considered essential to his employment and were based on Nasdaq Listing Rule 5635(c)(4). The stock options were granted at an exercise price of $4.32, coinciding with Protara's closing trading price on the date.
Additional Awards for New Employees
On the same day, Protara's Compensation Committee approved a total of 59,100 stock option awards and 29,550 RSUs for five additional hires, emphasizing the company's dedication to enhancing its workforce. These awards carry an exercise price of $3.46, reflecting Protara's closing trading price. The RSUs are scheduled to grant on July 1. All grants are subject to vesting terms that promote longevity within the company.
Understanding the Vesting Period
Vesting schedules are critical in ensuring that employees remain committed to the company. For the stock options, 25% will vest on the one-year anniversary of each grant, with the remainder vesting monthly over three years. RSUs will vest at a rate of 33 1/3% per year for three consecutive years. This structured approach not only retains valuable employees but also aligns their interests with the success of Protara.
About Protara Therapeutics
Protara is dedicated to developing groundbreaking therapies targeting severe conditions like cancer and rare diseases. Their principal investigational candidate, TARA-002, is designed for treating non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). Currently, TARA-002 is being tested in a Phase 2 trial focusing on NMIBC patients who are either unresponsive or have not previously responded to Bacillus Calmette-Guérin (BCG). Additionally, Protara is involved in a Phase 2 trial for pediatric patients suffering from LMs.
Innovative Developments
In addition to TARA-002, Protara holds another promising candidate, IV Choline Chloride, aimed at those who rely on parenteral nutrition and struggle to meet their choline needs. This investigational phospholipid substrate replacement showcases Protara's commitment to addressing critical nutritional gaps in vulnerable patient populations.
Connecting with Protara Therapeutics
The company invites interested parties to learn more about its groundbreaking initiatives and research by visiting www.protaratx.com. With a focus on innovation and patient care, Protara aims to transform medical outcomes for those in need.
Frequently Asked Questions
What is Protara Therapeutics known for?
Protara Therapeutics is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases, including non-muscle invasive bladder cancer.
How many stock options were granted to Shane Williams?
Shane Williams was awarded 41,000 stock option awards along with 20,500 restricted stock units (RSUs).
What is the exercise price of the stock options granted?
The exercise price for Shane Williams' stock options was set at $4.32 per share at the time of the grant.
What is the vesting schedule for the stock options?
The stock options vest over a period of four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
Where can I find more information about Protara?
Additional information about Protara Therapeutics can be found on their website at www.protaratx.com.
